Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
PLSE vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
PLSE vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $1.34B | $161.07B |
| Revenue (TTM) | $350K | $10.58B |
| Net Income (TTM) | $-73M | $2.98B |
| Gross Margin | -204.3% | 66.3% |
| Operating Margin | -219.8% | 30.5% |
| Forward P/E | — | 43.8x |
| Total Debt | $8M | $303M |
| Cash & Equiv. | $81M | $3.37B |
PLSE vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Pulse Biosciences, … (PLSE) | 100 | 215.5 | +115.5% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PLSE vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PLSE is the clearest fit if your priority is momentum.
- +17.4% vs ISRG's -15.4%
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.02
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs PLSE's 369.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs PLSE's -36.8% | |
| Quality / Margins | 28.2% margin vs PLSE's -207.9% | |
| Stability / Safety | Beta 1.02 vs PLSE's 1.94, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +17.4% vs ISRG's -15.4% | |
| Efficiency (ROA) | 14.8% ROA vs PLSE's -63.5%, ROIC 15.0% vs -8.8% |
PLSE vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PLSE vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 30234.6x PLSE's $350,000. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to PLSE's -207.9%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $350,000 | $10.6B |
| EBITDAEarnings before interest/tax | -$76M | $3.8B |
| Net IncomeAfter-tax profit | -$73M | $3.0B |
| Free Cash FlowCash after capex | -$54M | $2.8B |
| Gross MarginGross profit ÷ Revenue | -2.0% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -219.8% | +30.5% |
| Net MarginNet income ÷ Revenue | -207.9% | +28.2% |
| FCF MarginFCF ÷ Revenue | -155.5% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.2% | +18.8% |
Valuation Metrics
ISRG leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.3B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | -18.14x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x |
| EV / EBITDAEnterprise value multiple | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 3818.65x | 16.00x |
| Price / BookPrice ÷ Book value/share | 16.37x | 9.17x |
| Price / FCFMarket cap ÷ FCF | — | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-73 for PLSE. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PLSE's 0.09x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs PLSE's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -73.5% | +16.9% |
| ROA (TTM)Return on assets | -63.5% | +14.8% |
| ROICReturn on invested capital | -8.8% | +15.0% |
| ROCEReturn on capital employed | -73.1% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.09x | 0.02x |
| Net DebtTotal debt minus cash | -$73M | -$3.1B |
| Cash & Equiv.Liquid assets | $81M | $3.4B |
| Total DebtShort + long-term debt | $8M | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
PLSE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $11,423 for PLSE. Over the past 12 months, PLSE leads with a +17.4% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors PLSE at 34.7% vs ISRG's 14.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +46.3% | -19.3% |
| 1-Year ReturnPast 12 months | +17.4% | -15.4% |
| 3-Year ReturnCumulative with dividends | +144.3% | +49.6% |
| 5-Year ReturnCumulative with dividends | +14.2% | +58.7% |
| 10-Year ReturnCumulative with dividends | +369.8% | +554.2% |
| CAGR (3Y)Annualised 3-year return | +34.7% | +14.4% |
Risk & Volatility
ISRG leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than PLSE's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.94x | 1.02x |
| 52-Week HighHighest price in past year | $26.30 | $603.88 |
| 52-Week LowLowest price in past year | $12.56 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +74.5% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 240K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PLSE as "Buy" and ISRG as "Buy". Consensus price targets imply 53.1% upside for PLSE (target: $30) vs 37.3% for ISRG (target: $623).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $30.00 | $622.60 |
| # AnalystsCovering analysts | 4 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% |
ISRG leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PLSE leads in 1 (Total Returns).
PLSE vs ISRG: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PLSE or ISRG a better buy right now?
Intuitive Surgical, Inc.
(ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Pulse Biosciences, Inc. (PLSE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PLSE or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to +14. 2% for Pulse Biosciences, Inc. (PLSE). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus PLSE's +369. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PLSE or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 02β versus Pulse Biosciences, Inc. 's 1. 94β — meaning PLSE is approximately 91% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 9% for Pulse Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PLSE or ISRG?
On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc.
grew EPS 22. 6% year-over-year, compared to -17. 4% for Pulse Biosciences, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PLSE or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -207. 9% for Pulse Biosciences, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -219. 8% for PLSE. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PLSE or ISRG more undervalued right now?
Analyst consensus price targets imply the most upside for PLSE: 53.
1% to $30. 00.
07Which pays a better dividend — PLSE or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PLSE or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). Pulse Biosciences, Inc. (PLSE) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, PLSE: +369. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PLSE and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PLSE is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.